These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 23325085)

  • 21. [Treatment of children with steroid-dependent nephrotic syndrome with rituximab].
    Huang J; Du J; Wang S; Xiao L; Zhao X
    Zhonghua Er Ke Za Zhi; 2014 Jul; 52(7):521-4. PubMed ID: 25224058
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of Rituximab for Minimal Change Disease and Focal Segmental Glomerulosclerosis with Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome in Adults: A Chinese Multicenter Retrospective Study.
    Lan L; Lin Y; Yu B; Wang Y; Pan H; Wang H; Lou X; Lang X; Zhang Q; Jin L; Yang Y; Xiao L; Chen J; Han F
    Am J Nephrol; 2024; 55(1):25-36. PubMed ID: 37963441
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Could interleukin-17 be a therapeutic target of steroid-dependent minimal change disease?
    Eun Kim J; Il Shin J
    Kidney Int; 2013 Nov; 84(5):1049. PubMed ID: 24172738
    [No Abstract]   [Full Text] [Related]  

  • 24. Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome.
    Sinha A; Bhatia D; Gulati A; Rawat M; Dinda AK; Hari P; Bagga A
    Nephrol Dial Transplant; 2015 Jan; 30(1):96-106. PubMed ID: 25121488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rituximab for minimal change disease in adults: long-term follow-up.
    Bruchfeld A; Benedek S; Hilderman M; Medin C; Snaedal-Jonsdottir S; Korkeila M
    Nephrol Dial Transplant; 2014 Apr; 29(4):851-6. PubMed ID: 24121763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amelioration of the adverse effects of prednisolone by rituximab treatment in adults with steroid-dependent minimal-change nephrotic syndrome.
    Miyabe Y; Takei T; Iwabuchi Y; Moriyama T; Nitta K
    Clin Exp Nephrol; 2016 Feb; 20(1):103-10. PubMed ID: 26138356
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adult minimal-change disease: clinical characteristics, treatment, and outcomes.
    Waldman M; Crew RJ; Valeri A; Busch J; Stokes B; Markowitz G; D'Agati V; Appel G
    Clin J Am Soc Nephrol; 2007 May; 2(3):445-53. PubMed ID: 17699450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience.
    Hart PA; Topazian MD; Witzig TE; Clain JE; Gleeson FC; Klebig RR; Levy MJ; Pearson RK; Petersen BT; Smyrk TC; Sugumar A; Takahashi N; Vege SS; Chari ST
    Gut; 2013 Nov; 62(11):1607-15. PubMed ID: 22936672
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome.
    Kemper MJ; Gellermann J; Habbig S; Krmar RT; Dittrich K; Jungraithmayr T; Pape L; Patzer L; Billing H; Weber L; Pohl M; Rosenthal K; Rosahl A; Mueller-Wiefel DE; Dötsch J
    Nephrol Dial Transplant; 2012 May; 27(5):1910-5. PubMed ID: 22076431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review.
    Kronbichler A; Kerschbaum J; Fernandez-Fresnedo G; Hoxha E; Kurschat CE; Busch M; Bruchfeld A; Mayer G; Rudnicki M
    Am J Nephrol; 2014; 39(4):322-30. PubMed ID: 24751753
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Long-term prognosis of patients with steroid-dependent nephrotic syndrome treated with rituximab].
    Kamei K; Okada M; Miyazono A; Sato M; Fujimaru T; Ogura M; Ito S
    Nihon Jinzo Gakkai Shi; 2013; 55(5):947-55. PubMed ID: 23980480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome.
    Ruggenenti P; Ruggiero B; Cravedi P; Vivarelli M; Massella L; Marasà M; Chianca A; Rubis N; Ene-Iordache B; Rudnicki M; Pollastro RM; Capasso G; Pisani A; Pennesi M; Emma F; Remuzzi G;
    J Am Soc Nephrol; 2014 Apr; 25(4):850-63. PubMed ID: 24480824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rituximab in adult patients with multi-relapsing/steroid-dependent minimal change disease and focal segmental glomerulosclerosis: a report of 5 cases.
    Kronbichler A; König P; Busch M; Wolf G; Mayer G; Rudnicki M
    Wien Klin Wochenschr; 2013 Jun; 125(11-12):328-33. PubMed ID: 23624956
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of mycophenolate mofetil in pediatric patients with steroid-dependent nephrotic syndrome.
    Novak I; Frank R; Vento S; Vergara M; Gauthier B; Trachtman H
    Pediatr Nephrol; 2005 Sep; 20(9):1265-8. PubMed ID: 15942779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of rituximab treatment in children with primary glomerulonephritis.
    Zachwieja J; Silska M; Ostalska-Nowicka D; Soltysiak J; Lipkowska K; Blumczynski A; Musielak A
    J Nephrol; 2012; 25(6):1060-6. PubMed ID: 22322817
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tacrolimus versus intravenous pulse cyclophosphamide therapy in Chinese adults with steroid-resistant idiopathic minimal change nephropathy: a multicenter, open-label, nonrandomized cohort trial.
    Li H; Shi X; Shen H; Li X; Wang H; Li H; Xu G; Chen J
    Clin Ther; 2012 May; 34(5):1112-20. PubMed ID: 22503105
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab.
    Kamei K; Ishikura K; Sako M; Aya K; Tanaka R; Nozu K; Kaito H; Nakanishi K; Ohtomo Y; Miura K; Takahashi S; Morimoto T; Kubota W; Ito S; Nakamura H; Iijima K;
    Pediatr Nephrol; 2017 Nov; 32(11):2071-2078. PubMed ID: 28664242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frequent-relapsing, steroid-dependent minimal change disease: is rituximab the answer?
    Fervenza FC; Sethi S
    Nephrol Dial Transplant; 2014 Apr; 29(4):722-7. PubMed ID: 24026241
    [No Abstract]   [Full Text] [Related]  

  • 39. Rituximab: effective treatment for severe steroid-dependent minimal change nephrotic syndrome?
    Hofstra JM; Deegens JK; Wetzels JF
    Nephrol Dial Transplant; 2007 Jul; 22(7):2100-2. PubMed ID: 17389619
    [No Abstract]   [Full Text] [Related]  

  • 40. Efficacy and safety of leflunomide in treatment of steroid-dependent and steroid-resistant adult onset minimal change disease.
    Zhou J; Zhang Y; Liu G; Li J; Xu R; Huang J
    Clin Nephrol; 2013 Aug; 80(2):121-9. PubMed ID: 23458173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.